Supplementary Data for "GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"

sMethod 1. Search strategy
sTable 1. Baseline characteristics of studies and participants included
sTable 2. Risks of bias assessment of eligible studies
sTable 3. Subgroup analysis to study effect of factors on association of GLP-1RAs treatment with adverse cerebrovascular outcomes
sTable 4. GRADE summary of findings for outcomes in the meta-analysis
sFigure 1. PRISMA flow diagram
sFigure 2. Risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs compared with controls
sFigure 3A-B: Risks of stroke (fatal or nonfatal) outcomes in patients treated with GLP-1 RAs compared with placebo
[3A: pooled risk ratios, 3B: pooled hazard ratio]
sFigure 4: Risks of fatal stroke outcomes in patients treated with GLP-1 RAs compared with placebo
sFigure 5: Risks of nonfatal stroke outcomes in patients treated with GLP-1 RAs compared with placebo
sFigure 6. Risks of ischemic stroke outcomes in patients treated with GLP-1 RAs compared with controls
sFigure 7. Risks of composite of ischemic stroke or transient ischemic attacks in patients treated with GLP-1 RAs compared with controls
sFigure 8. Risks of hemorrhagic stroke in patients treated with GLP-1 RAs compared with controls
sFigure 9. Effect of nature of trials on risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs versus controls
sFigure 10: Effect of control group on risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs versus controls
sFigure 11: Effect of structural homology of GLP-1RAs on risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs versus controls
sFigure 12: Effect of treatment duration on risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs versus controls
sFigure 13A-E: Effect of baseline characteristics of trial participants on risks of adverse cerebrovascular outcomes in patients treated with GLP-1 RAs versus controls [13A: Age; 13B: BMI; 13C: eGFR; 13D: HbA1c; 13E: Diabetes duration]
sFigure 14. Effect of individual GLP-1RAs on adverse cerebrovascular outcomes
sFigure 15. Sensitivity analysis of effects of GLP-1RAs on adverse cerebrovascular outcomes after excluding RCTs on lixisenatide
sFigure 16. Funnel plots and Egger’s test results of all trials for each outcome reported